Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAT2A | P31153 | 4/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25283774 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1HSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL12246354 | 0.76 | AXL (0.41) | TGFBR1ALDH1A1P2RX7GAA | |
| SCHEMBL18306004 | 0.74 | ADORA2A (0.65) | ADORA2AADORA1HSD17B10KDM4ECCR8 | |
| SCHEMBL2118961 | 0.74 | FABP4 (0.37) | HSD17B10KDM4ESMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL8039008 | 0.73 | ADORA1 (1.00) | ADORA2AADORA1KDM4ECCR8KMT2A | |
| SCHEMBL4192610 | 0.72 | KDM4E (0.44) | HSD17B10KDM4EALDH1A1GAA | |
| SCHEMBL20354826 | 0.71 | TRPV4 (0.42) | ADORA1KDM4EKMT2ATGFBR1ALDH1A1 | |
| SCHEMBL20354827 | 0.71 | MET (0.35) | MAT2AGAA | |
| SCHEMBL702514 | 0.70 | AXL (0.44) | ALDH1A1MAT2AGAA | |
| SCHEMBL23106895 | 0.70 | TGFBR1 (0.36) | ADORA2AADORA1KDM4ETGFBR1MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3496715-B1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE | MERCK SHARP & DOHME (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10414775-B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190218224-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414775-B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | CYP27A1, CYP7A1, CYP7B1 | ADORA2A 2830/4885ADORA1 1961/4885HSD17B10 48/4885 |
| US-20190218224-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | CYP27A1, CYP7B1, CYP7A1 | ADORA2A 2868/4885ADORA1 2172/4885HSD17B10 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.